
Last updated: 2026-10-19 21:11:40. Prices reflect the latest after-hours trading data. Stock price data is sourced from Massive.
Kura Oncology, Inc. (KURA) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $9.36, with a market capitalization of $807.76M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $7.36 to $13.90. This page covers its latest market performance, valuation, price trends and company information.
$807.76M | |
$9.17 | |
$43.00 | |
$2.50 | |
$9.08 | |
1.87M | |
1.84M | |
-- | |
$13.90 | |
$7.36 | |
-- | |
-- |
Kura Oncology, Inc. (KURA) is trading at $9.56 in after-hours trading as of 2026-10-19 20:52:00, up 5.28% ($0.48) from the regular-session close of $9.08.
After-hours trading shows how investors are pricing KURA after the regular session closes. The current after-hours price is above the regular-session close, indicating positive after-hours sentiment.
Over the past seven days, Kura Oncology, Inc. (KURA) moved from $10.52 to $9.36, representing a decline of 11.06% ($1.16).
The stock traded between $8.94 and $10.68 during the period. The latest price is near the lower end of the 7-day range, indicating strong downward.
The average daily volume was 1.76 million shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 30.6%
KURA is currently trading at $9.36, placing it 30.6% of the way from its 52-week low of $7.36 to its 52-week high of $13.90. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Kura Oncology Inc is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies for the treatment of cancer. The company develops small-molecule medicines designed to target cancer signaling pathways in oncology and hematology. Its pipeline includes menin inhibitor ziftomenib for the treatment of acute myeloid leukemia and other hematologic malignancies, as well as additional product candidates such as KO-7246 and darolifarnib being evaluated for solid tumors and other diseases.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 260 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Kura Oncology, Inc. (KURA) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.